Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 December 2024
Avapritinib for treating advanced systemic mastocytosis ID3770Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 October 2024
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 August 2024
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 June 2024
Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over ID6342Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Suspected sepsis: recognition, diagnosis and early managementStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 August 2025
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024
Voxelotor for treating sickle cell disease [ID1403]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 June 2024